

May 2, 2014



SCYNEXIS Announces Pricing of Initial Public Offering

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq: SCYX) today announced the pricing of its initial public offering of 6,200,000 shares of its common stock at a public offering price of \$10.00 per share, before underwriting discounts and commissions. All of the shares of common stock are being offered by SCYNEXIS. In addition, SCYNEXIS has granted the underwriters a 30-day option to purchase up to an additional 930,000 shares of common stock at the initial public offering price less the underwriting discounts and commissions to cover over-allotments, if any. The company's shares are expected to begin trading on The NASDAQ Global Market on May 2, 2014, under the ticker symbol "SCYX".

RBC Capital Markets and Canaccord Genuity are acting as joint book-running managers. JMP Securities is participating as lead manager in the offering.

A registration statement relating to the securities being sold in this offering has been filed with the U.S. Securities and Exchange Commission and was declared effective on May 2, 2014. This offering is being made only by means of a written prospectus forming part of the effective registration statement. Copies of the final prospectus, when available, may be obtained on the SEC EDGAR Filings Website: <http://www.sec.gov/>, or from RBC Capital Markets, LLC, Attention: Prospectus Department, Three World Financial Center, 200 Vesey Street 8th Floor, New York, NY 10281, telephone (877) 822-4089 or Canaccord Genuity Inc., Attn: Syndicate Department, 99 High Street, 12th Floor, Boston, MA 02110, telephone (617) 371-3900.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About SCYNEXIS, Inc.

SCYNEXIS is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. SCYNEXIS is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. In addition, SCYNEXIS has clinical and preclinical programs based on the use of cyclophilin inhibitors to treat viral diseases, as well as contract research and development services primarily in the field of animal health. www.scynexis.com.

Company

SCYNEXIS

Amanda Mancuso, 919-544-8663

Chief of Staff

amanda.mancuso@scynexis.com

or

Media Relations

MacDougall Biomedical Communications

Cory Tromblee, 781-235-3060

ctromblee@macbiocom.com

Source: SCYNEXIS, Inc.